Drawing for BRELGA

USPTO serial 86349915

BRELGA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
ALTREE, NICHOLAS
Law office
TMEG LAW OFFICE 107 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with BRELGA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher M. Hanes

CHRISTOPHER M. HANES GlaxoSmithKlineFive Moore DriveLegal Global Trademarks, Mailstop: 5.5AResearch Triangle Park, NC 27709-0183

Goods and services

ClassDescriptionStatusFirst use
005(Based on Intent to Use) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; VaccinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Nov 30, 2015MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 27, 2015ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 22, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 11, 2015GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
May 11, 2015GNSIINQUIRY TO SUSPENSION E-MAILED—
May 11, 2015CNSISUSPENSION INQUIRY WRITTEN—
Nov 10, 2014GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Nov 10, 2014GNSLLETTER OF SUSPENSION E-MAILED—
Nov 10, 2014CNSLSUSPENSION LETTER WRITTEN—
Nov 10, 2014DOCKASSIGNED TO EXAMINER—
Aug 5, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 31, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance